{"id":8357,"date":"2022-01-13T09:07:42","date_gmt":"2022-01-13T09:07:42","guid":{"rendered":"https:\/\/ncrfrontlinenews.com\/?p=8357"},"modified":"2022-01-13T09:07:42","modified_gmt":"2022-01-13T09:07:42","slug":"covaxin-can-neutralise-delta-omicron-variants-of-coronavirus-bharat-biotech","status":"publish","type":"post","link":"https:\/\/ncrfrontlinenews.com\/?p=8357","title":{"rendered":"Covaxin can neutralise Delta, Omicron variants of coronavirus: Bharat Biotech"},"content":{"rendered":"<p>New Delhi: Hyderabad-based Bharat Biotech on Wednesday claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.<\/p>\n<p>In a statement, Bharat Biotech said, \u201cResults from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants.\u201d<\/p>\n<p>It also mentioned that earlier studies demonstrated the neutralizing potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa. The study will be published on the pre-print server, medRXiv, shortly.<\/p>\n<p>Sera samples from individuals who received a booster of Covaxin were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay.<\/p>\n<p>The Hyderabad based company claimed that the neutralization activity of Covaxin boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant and found more than 90 per cent of all individuals boosted with Covaxin showed neutralizing antibodies.<\/p>\n<p>All participants received an initial two-dose schedule of Covaxin on Day 0 and Day 28.<\/p>\n<p>\u201cAs the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern,\u201d said Mehul Suthar, PhD Assistant Professor, Emory Vaccine Center who led the laboratory analysis.<\/p>\n<p>Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations, said the statement.<\/p>\n<p>\u201cWe are in a continuous state of innovation and product development for Covaxin. The positive neutralization responses against the Omicron and Delta variants validate our hypothesis of a multi-epitope vaccine generating both humoral and cell-mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of Covasxin as a universal vaccine for adults and children,\u201d said Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi: Hyderabad-based Bharat Biotech on Wednesday claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus. In a statement, Bharat Biotech said, \u201cResults from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8358,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":{"0":"post-8357","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-national"},"_links":{"self":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/8357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8357"}],"version-history":[{"count":1,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/8357\/revisions"}],"predecessor-version":[{"id":8359,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/8357\/revisions\/8359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/media\/8358"}],"wp:attachment":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}